Artiva advances NK cell therapy to phase 3, secures 400 billion won funding Single phase 3 cleared by FDA after strong phase 2 ACR50 results; $300 million raised from global investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results